Dexcom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, announced today that Health Canada has authorized the ...
Dexcom anticipates that the findings could drive a shift in the standard of care for type 2 diabetes patients who do not use ...
The CGM provides real-time glucose readings for 15.5 days. “As a disabled veteran living with Type 2 diabetes, becoming a grandfather has given me a powerful new reason to take charge of my health,” ...
Zacks Investment Research on MSN
DXCM secures Health Canada authorization for Dexcom G7 15 day CGM
DexCom DXCM recently announced that the Dexcom G7 15 Day Continuous Glucose Monitoring (CGM) System has received ...
Numerous comments on a Facebook group called “Dexcom G7 – Issues and Complaints” has brought to light a problem that users are referring to as “goose necking.” MD+DI learned more about this issue – ...
Diabeloop, a pioneer in therapeutic artificial intelligence for diabetes management, today announces that DBLG2 ...
June 6 (Reuters) - Medical device maker Dexcom (DXCM.O), opens new tab said the use of its continuous glucose monitor, G7, led to improved blood sugar control in patients with type 2 diabetes not ...
DXCM reports positive CONNECT trial results as Dexcom G7 improves HbA1c and time in range in adults with Type 2 diabetes not using insulin.
Diabeloop, a pioneer in therapeutic artificial intelligence for diabetes management, today announced technical readiness, CE marking approval and the gradual European launch of its latest Automated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results